Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Total 13F shares
-
16,114,855
-
Share change
-
+7,797,561
-
Total reported value
-
$63,650,620
-
Price per share
-
$3.95
-
Number of holders
-
44
-
Value change
-
+$30,828,789
-
Number of buys
-
39
-
Number of sells
-
1
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q1 2019
As of 31 Mar 2019,
Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,114,855 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, EMERALD MUTUAL FUND ADVISERS TRUST, RTW INVESTMENTS, LP, VANGUARD GROUP INC, Schonfeld Strategic Advisors LLC, Manatuck Hill Partners, LLC, MILLENNIUM MANAGEMENT LLC, BRIDGEWAY CAPITAL MANAGEMENT INC, DEUTSCHE BANK AG\, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
44
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.